In one study, PTK6 inhibition led to an increase in apoptosis of lapatinib-resistant HER2+ breast cancer cell lines (21), while inhibition of SRC kinase by SRC kinase inhibitors restored lapatinib sensitivity, in a different study (22). Here, ERBB2 is linked to breast carcinoma.